CD274 and non-small cell lung carcinoma: The subsequent KEYNOTE-024 study confirmed the sustained efficacy of a TPS ≥ 50% cutoff for pembrolizumab monotherapy as a first-line treatment in NSCLC patients with PD-L1 TPS ≥ 50%.